Altering the immune response with lipid-based nanoparticles.

Lipid-based nanoparticles (LNPs) hold great promise as delivery vectors in the treatment of cancer, inflammation, and infections and are already used in clinical practice. Numerous strategies based on LNPs are being developed to carry drugs into specific target sites. The common denominator for all of these LNPs-based platforms is to improve the payloads' pharmacokinetics, biodistribution, stability and therapeutic benefit, and to reduce to minimal adverse effects. In addition, the delivery system must be biocompatible and non-toxic and avoid undesirable interactions with the immune system. In order to achieve optimal benefits from these delivery strategies, interactions with the immune system must be thoroughly investigated. This report will center on the interactions of LNPs with different subsets of leukocytes and will detail representative examples of suppression or activation of the immune system by these carriers. By understanding the interactions of LNPs with the innate and the adaptive arms of the immune system it might be possible to attain improved therapeutic benefits and to avoid immune toxicity.

[1]  Anil K Sood,et al.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. , 2005, Cancer research.

[2]  D. Peer,et al.  Integrin-targeted nanoparticles for siRNA delivery. , 2011, Methods in molecular biology.

[3]  E. Agger,et al.  Cationic liposomes as vaccine adjuvants , 2007, Expert review of vaccines.

[4]  J. Rossi,et al.  RNAi-based therapeutics–current status, challenges and prospects , 2009, EMBO molecular medicine.

[5]  H. Maeda,et al.  Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Nathan F. Bouxsein,et al.  Synthesis and characterization of degradable multivalent cationic lipids with disulfide-bond spacers for gene delivery. , 2011, Biochimica et biophysica acta.

[7]  H. Maeda,et al.  Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.

[8]  I. Toth,et al.  Particulate systems as adjuvants and carriers for peptide and protein antigens. , 2006, Current drug delivery.

[9]  P. Schulze-Lefert,et al.  NLR functions in plant and animal immune systems: so far and yet so close , 2011, Nature Immunology.

[10]  T. Casale,et al.  Immune modulation for treatment of allergic disease , 2011, Immunological reviews.

[11]  R. Schwendener,et al.  Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach , 2006, British Journal of Cancer.

[12]  M. Entman,et al.  The inflammatory response in myocardial infarction. , 2002, Cardiovascular research.

[13]  Liz Y. Han,et al.  Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. , 2008, Journal of the National Cancer Institute.

[14]  David Leong,et al.  Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. , 2007, Molecular pharmaceutics.

[15]  D. Peer,et al.  Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target , 2008, Science.

[16]  D. Peer,et al.  Systemic siRNA delivery to leukocyte-implicated diseases , 2009, Cell cycle.

[17]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[18]  M. King,et al.  An immobilized nanoparticle-based platform for efficient gene knockdown of targeted cells in the circulation , 2009, Gene Therapy.

[19]  Yvonne Perrie,et al.  Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[20]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[21]  B. Beutler,et al.  TLR signaling pathways: opportunities for activation and blockade in pursuit of therapy. , 2006, Current pharmaceutical design.

[22]  A. Gewirtz.  On future's doorstep: RNA interference and the pharmacopeia of tomorrow. , 2007, The Journal of clinical investigation.

[23]  J. Lieberman,et al.  Special delivery: targeted therapy with small RNAs , 2011, Gene Therapy.

[24]  A. Sood,et al.  Nanomedicine based approaches for the delivery of siRNA in cancer , 2010, Journal of internal medicine.

[25]  Motohiko Suzuki,et al.  A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. , 2009, Blood.

[26]  Leaf Huang,et al.  Immunostimulation of dendritic cells by cationic liposomes , 2006, Molecular membrane biology.

[27]  S. Wise.  Nanocarriers as an emerging platform for cancer therapy , 2007 .

[28]  J. Ruysschaert,et al.  Cationic liposomal lipids: from gene carriers to cell signaling. , 2008, Progress in lipid research.

[29]  Dan Peer,et al.  Reshaping the future of nanopharmaceuticals: ad iudicium. , 2011, ACS nano.

[30]  T. Ishida,et al.  Accelerated clearance of a second injection of PEGylated liposomes in mice. , 2003, International journal of pharmaceutics.

[31]  X. Xuan,et al.  Immunization with Oligomannose-Coated Liposome-Entrapped Dense Granule Protein 7 Protects Dams and Offspring from Neospora caninum Infection in Mice , 2009, Clinical and Vaccine Immunology.

[32]  J. Leor,et al.  Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair , 2011, Proceedings of the National Academy of Sciences.

[33]  M. Behlke.  Chemical modification of siRNAs for in vivo use. , 2008, Oligonucleotides.

[34]  G. Golomb,et al.  Alendronate liposomes for antitumor therapy: activation of γδ T cells and inhibition of tumor growth. , 2012, Advances in experimental medicine and biology.

[35]  Miklós Tóth,et al.  Animal Models of Complement-Mediated Hypersensitivity Reactions to Liposomes and Other Lipid-Based Nanoparticles , 2007, Journal of liposome research.

[36]  John J. Rossi,et al.  Strategies for silencing human disease using RNA interference , 2007, Nature Reviews Genetics.

[37]  Mauro Ferrari,et al.  Sustained small interfering RNA delivery by mesoporous silicon particles. , 2010, Cancer research.

[38]  S. Gordon,et al.  Scavenger receptors in innate immunity. , 2002, Current opinion in immunology.

[39]  D. Dykxhoorn,et al.  Advances in synthetic siRNA delivery. , 2010, Discovery medicine.

[40]  Marius A. Micluţa,et al.  Coiled-coil domain-dependent homodimerization of intracellular barley immune receptors defines a minimal functional module for triggering cell death. , 2011, Cell host & microbe.

[41]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[42]  D. Nemazee,et al.  Immunology: Toll-like receptors and antibody responses , 2006, Nature.

[43]  Taro Shimizu,et al.  PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[44]  G. Golomb,et al.  Preparation of Alendronate Liposomes for Enhanced Stability and Bioactivity: In Vitro and In Vivo Characterization , 2008, The AAPS Journal.

[45]  T M Allen,et al.  Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.

[46]  M. Dobrovolskaia,et al.  Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.

[47]  Andrew D. Miller,et al.  Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. , 2004, Biochemistry.

[48]  S. Akhtar,et al.  Nonviral delivery of synthetic siRNAs in vivo. , 2007, The Journal of clinical investigation.

[49]  P. Couvreur,et al.  Nanotechnology: Intelligent Design to Treat Complex Disease , 2006, Pharmaceutical Research.

[50]  Jie Li,et al.  Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors1 , 2004, The Journal of Immunology.

[51]  Y. Ikehara,et al.  Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[52]  Yechezkel Barenholz,et al.  Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[53]  Zhengfan Jiang,et al.  Genetic analysis of innate immunity. , 2006, Advances in immunology.

[54]  D. Peer,et al.  Antibody-mediated delivery of siRNAs for anti-HIV therapy. , 2011, Methods in molecular biology.

[55]  C. Foged,et al.  Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators , 2009, Expert opinion on drug delivery.

[56]  F M Muggia,et al.  ROLE OF COMPLEMENT ACTIVATION IN HYPERSENSITIVITY REACTIONS TO DOXIL AND HYNIC PEG LIPOSOMES: EXPERIMENTAL AND CLINICAL STUDIES , 2002, Journal of liposome research.

[57]  오연균.  Surfactant의 광범위 이용 , 2003 .

[58]  S. Rosenberg.  Progress in the development of immunotherapy for the treatment of patients with cancer , 2001, Journal of internal medicine.

[59]  M. Behlke,et al.  Chemical modification and design of anti-miRNA oligonucleotides , 2011, Gene Therapy.

[60]  Sven Frokjaer,et al.  Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. , 2004, Vaccine.

[61]  Seyed Moein Moghimi,et al.  Liposome triggering of innate immune responses: A perspective on benefits and adverse reactions , 2009, Journal of liposome research.

[62]  Theresa A. Storm,et al.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.

[63]  Dan R. Littman,et al.  Th17 and Regulatory T Cells in Mediating and Restraining Inflammation , 2010, Cell.

[64]  D. Peer,et al.  RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[65]  Jian Qin,et al.  The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. , 2006, Nano letters.

[66]  Ying S. Chao,et al.  Role of carbohydrate receptors in the macrophage uptake of dextran-coated iron oxide nanoparticles. , 2012, Advances in experimental medicine and biology.

[67]  Takeshi Kobayashi,et al.  A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. , 2006, Cancer research.

[68]  F M Muggia,et al.  Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  D. Peer,et al.  Grand challenges in modulating the immune response with RNAi nanomedicines. , 2011, Nanomedicine.

[70]  G. Golomb,et al.  Route of administration-dependent anti-inflammatory effect of liposomal alendronate. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[71]  Liz Y. Han,et al.  Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy , 2006, Clinical Cancer Research.

[72]  N. Ali,et al.  Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route. , 2012, Molecular pharmaceutics.

[73]  R. Müller,et al.  Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. , 2001, International journal of pharmaceutics.

[74]  H. Nakanishi,et al.  Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells. , 2008, Cancer letters.

[75]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[76]  M. Jaafari,et al.  Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits. , 2009, Colloids and surfaces. B, Biointerfaces.

[77]  Justine R. Smith,et al.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 , 2008, Nature.

[78]  Luís Eduardo Coelho Andrade,et al.  Sistema imunitário: Parte I. Fundamentos da imunidade inata com ênfase nos mecanismos moleculares e celulares da resposta inflamatória , 2010 .

[79]  A. Sood,et al.  Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. , 2008, Cancer research.

[80]  N. Van Rooijen,et al.  Delayed graft rejection in pre-vascularised corneas after subconjunctival injection of clodronate liposomes , 2000 .

[81]  M. Cooper,et al.  The evolution of adaptive immunity. , 2006, Annual review of immunology.

[82]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[83]  L. Ellis,et al.  Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. , 2008, Journal of the National Cancer Institute.

[84]  D. Peer,et al.  Overcoming RNAi transduction in leukocytes using targeted and stabilized nanoparticles. , 2010, IDrugs : the investigational drugs journal.

[85]  P. Richards,et al.  Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate. , 2001, Rheumatology.

[86]  D. Irvine,et al.  Particulate vaccines: on the quest for optimal delivery and immune response. , 2011, Drug discovery today.

[87]  Yechezkel Barenholz,et al.  Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. , 2011, Advanced drug delivery reviews.

[88]  R. Müller,et al.  Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. , 2002, International journal of pharmaceutics.

[89]  R. Birge,et al.  The Presumptive Phosphatidylserine Receptor Is Dispensable for Innate Anti-inflammatory Recognition and Clearance of Apoptotic Cells* , 2006, Journal of Biological Chemistry.

[90]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[91]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[92]  Dan Peer,et al.  The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. , 2010, Biomaterials.

[93]  M. Jenkins,et al.  Origins of CD4+ effector and central memory T cells , 2011, Nature Immunology.

[94]  D. Dykxhoorn,et al.  Breaking down the barriers: siRNA delivery and endosome escape , 2010, Journal of Cell Science.

[95]  L. Andrade,et al.  Immune system - part I. Fundamentals of innate immunity with emphasis on molecular and cellular mechanisms of inflammatory response. , 2010, Revista brasileira de reumatologia.

[96]  D. Littman,et al.  Plasticity of CD4+ T cell lineage differentiation. , 2009, Immunity.

[97]  Jun Li,et al.  Multifunctional Nanoparticles Delivering Small Interfering RNA and Doxorubicin Overcome Drug Resistance in Cancer* , 2010, The Journal of Biological Chemistry.

[98]  C. Miller,et al.  Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. , 1998, Biochemistry.

[99]  V. Torchilin,et al.  Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[100]  C. Rooney,et al.  Improving T cell therapy for cancer. , 2007, Expert opinion on biological therapy.

[101]  Y. Tsutsumi,et al.  Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins. , 1997, Biochemical and biophysical research communications.

[102]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[103]  J. Tschopp,et al.  Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β , 2010, Proceedings of the National Academy of Sciences.

[104]  J. Lieberman,et al.  Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1 , 2007, Proceedings of the National Academy of Sciences.

[105]  T. Ishida,et al.  Accelerated clearance of PEGylated liposomes in rats after repeated injections. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[106]  Marina A Dobrovolskaia,et al.  Nanoparticles and the immune system. , 2010, Endocrinology.

[107]  Y. Ikehara,et al.  Recent Advancements in Cytotoxic T Lymphocyte Generation Methods Using Carbohydrate-Coated Liposomes , 2010, Journal of biomedicine & biotechnology.

[108]  S. Durham,et al.  Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. , 2009, The Journal of clinical investigation.

[109]  Michael H. Shuman,et al.  Assessing cellular toxicities in fibroblasts upon exposure to lipid-based nanoparticles: a high content analysis approach , 2011, Nanotechnology.